Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Galapagos

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              First Patient Dosed with Galapagos' GLPG3667 in Psoriasis Patient Phase 1b Trial

              Contact the Supplier

              Lead Product(s): GLPG3667

              Therapeutic Area: Dermatology Product Name: GLPG3667

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 09, 2020

              Details:

              This Phase 1b trial is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of GLPG3667.

              Galapagos

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Galapagos Announces First Dosing with Toledo Compound GLPG3970 in Psoriasis Trial

              Contact the Supplier

              Lead Product(s): GLPG3970

              Therapeutic Area: Dermatology Product Name: GLPG3970

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 29, 2020

              Details:

              Patient enrolled in the Calosoma Phase 1 trial, a double-blind, placebo-controlled study evaluating the safety, tolerability, PK and PD1 of GLPG3970 single and multiple ascending doses in up to 52 adult healthy male subjects.

              PharmaCompass__DigitalAd